Subscribe

Revenio Group Oyj (REG1V.HE)

EUR12.64 +0.24 (+1.94%)
FI HEL Healthcare Medical - Specialties
Address Äyritie 22 1510
Vantaa, FI
CEO Jouni Erik Toijala
Website reveniogroup.fi
IPO 2008-11-20
ISIN FI0009010912

Explore sections of this company profile

Also trades on London Stock Exchange · 0KFH.L (EUR) NASDAQ Helsinki · REG1V.HE (EUR)
Description

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used for measuring IOP on animal patients by general veterinary practitioners, veterinary ophthalmologists and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR12.64 +0.24 (+1.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
70.2K
Beta
0.84
Float Shares
20.01M
Free Float %
75.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+4.32% -0.57% +0.86% -24.62% -37.13% -36.56% -48.83% -54.21% -77.87% +78.60% -14.15%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
12.64
DCF (Unlevered) 20.06 +58.7%
DCF (Levered) 19.56 +54.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 80% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 3 -1
Hold 1 +1
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
8.98
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
7 / 10
Strong MOAT
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Specialties: +8.3%
    +6.0% Q1'26: +4.6% (vs Q1'25)
  • ✗
    EPS growth Medical - Specialties: +10.1%
    -5.7% Q1'26: -42.5% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Specialties: +51.3%
    +19.9% Q1'26: -16.1% (vs Q1'25)
  • ✓
    EBIT margin Medical - Specialties: +12.6%
    +23.2% ★ Q1'26: +8.4% (vs Q1'25)
  • ✓
    ROIC Medical - Specialties: +6.6%
    +19.5% ★ Q1'26: +6.9% (vs Q1'25)
  • ✓
    Share dilution Medical - Specialties: 0.0%
    -0.1% ★ Q1'26: +2.2% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×
    0.37× ★ Q1'26: 0.35× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.85) × ERP
WACC = 97% × Ke + 3% × Kd (23.7%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 20.06 Current price: 12.64
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
3 Rev. Ana.
3 EPS Ana. 		Dec 2027
3 Rev. Ana.
3 EPS Ana. 		Dec 2028
3 Rev. Ana.
3 EPS Ana. 		Dec 2029
2 Rev. Ana.
1 EPS Ana.
Revenue
20.25M
est: 20.65M (-1.9%)
23.43M
est: 23.50M (-0.3%)
26.79M
est: 26.50M (+1.1%)
30.66M
est: 30.90M (-0.8%)
49.47M
est: 50.08M (-1.2%)
61.07M
est: 60.23M (+1.4%)
78.78M
est: 78.86M (-0.1%)
96.98M
est: 97.14M (-0.2%)
96.58M
est: 100.49M (-3.9%)
103.50M
est: 103.81M (-0.3%)
109.70M
est: 111.07M (-1.2%)
149.37M
148.26M – 151.41M
+34.5% YoY
189.27M
184.92M – 192.36M
+26.7% YoY
171.42M
168.75M – 174.00M
-9.4% YoY
234.06M
230.41M – 237.59M
+36.5% YoY
EBITDA
6.49M
est: 6.55M (-1.0%)
7.80M
est: 7.46M (+4.6%)
10.44M
est: 8.41M (+24.1%)
10.80M
est: 9.81M (+10.1%)
14.60M
est: 15.89M (-8.1%)
19.58M
est: 19.11M (+2.4%)
25.34M
est: 25.03M (+1.3%)
32.79M
est: 30.83M (+6.4%)
30.09M
est: 30.93M (-2.7%)
30.52M
est: 31.95M (-4.5%)
29.90M
est: 34.18M (-12.5%)
45.97M
45.63M – 46.60M
+34.5% YoY
58.25M
56.91M – 59.20M
+26.7% YoY
52.76M
51.94M – 53.55M
-9.4% YoY
72.04M
70.91M – 73.12M
+36.5% YoY
EBIT
5.92M
est: 5.70M (+3.8%)
7.12M
est: 6.49M (+9.8%)
8.29M
est: 7.31M (+13.4%)
10.24M
est: 8.53M (+20.1%)
12.49M
est: 13.82M (-9.6%)
16.97M
est: 16.62M (+2.1%)
22.35M
est: 21.76M (+2.7%)
29.32M
est: 26.81M (+9.4%)
26.11M
est: 26.80M (-2.6%)
25.31M
est: 27.69M (-8.6%)
25.40M
est: 29.62M (-14.3%)
39.84M
39.54M – 40.38M
+34.5% YoY
50.48M
49.32M – 51.30M
+26.7% YoY
45.72M
45.00M – 46.41M
-9.4% YoY
62.42M
61.45M – 63.36M
+36.5% YoY
Net Income
6.50M
est: 6.05M (+7.3%)
5.58M
est: 6.65M (-16.0%)
6.85M
est: 8.07M (-15.1%)
8.10M
est: 9.27M (-12.6%)
9.34M
est: 10.73M (-12.9%)
13.36M
est: 13.35M (+0.1%)
17.32M
est: 18.56M (-6.7%)
21.75M
est: 23.62M (-7.9%)
19.11M
est: 19.31M (-1.0%)
18.50M
est: 19.63M (-5.8%)
17.40M
est: 19.64M (-11.4%)
22.39M
19.78M – 25.00M
+14.0% YoY
25.79M
24.32M – 26.82M
+15.2% YoY
29.10M
26.27M – 30.84M
+12.9% YoY
35.77M
35.05M – 36.47M
+22.9% YoY
SGA
3.76M
est: 2.62M (+43.4%)
3.35M
est: 2.98M (+12.3%)
3.48M
est: 3.36M (+3.4%)
4.60M
est: 3.92M (+17.2%)
8.51M
est: 6.36M (+33.9%)
6.58M
est: 7.64M (-13.9%)
9.11M
est: 10.01M (-9.0%)
11.05M
est: 12.33M (-10.4%)
12.58M
est: 10.59M (+18.8%)
17.29M
est: 10.94M (+58.1%)
—
est: 11.70M (-100.0%)
15.74M
15.62M – 15.95M
+34.5% YoY
19.94M
19.48M – 20.27M
+26.7% YoY
18.06M
17.78M – 18.33M
-9.4% YoY
24.66M
24.28M – 25.03M
+36.5% YoY
EPS
0.28
est: 0.23 (+23.0%)
0.23
est: 0.25 (-8.0%)
0.29
est: 0.30 (-4.4%)
0.34
est: 0.35 (-2.5%)
0.36
est: 0.40 (-10.7%)
0.50
est: 0.50 (-0.4%)
0.65
est: 0.70 (-6.9%)
0.82
est: 0.89 (-7.7%)
0.72
est: 0.73 (-1.3%)
0.70
est: 0.74 (-5.3%)
0.66
est: 0.74 (-10.8%)
0.84
0.74 – 0.94
+13.3% YoY
0.97
0.92 – 1.01
+15.3% YoY
1.09
0.99 – 1.16
+12.7% YoY
1.35
1.32 – 1.37
+23.6% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B+ 3/5 4/5 4/5 5/5 3/5 1/5 2/5
2026-05-28 B+ 3/5 4/5 4/5 5/5 3/5 1/5 2/5
2026-05-27 B+ 3/5 4/5 4/5 5/5 3/5 1/5 2/5
2026-05-26 B+ 3/5 4/5 4/5 5/5 3/5 1/5 2/5
2026-05-25 B+ 3/5 4/5 4/5 5/5 3/5 1/5 2/5
2026-05-22 B+ 3/5 4/5 4/5 5/5 3/5 1/5 2/5
2026-05-21 B+ 3/5 4/5 4/5 5/5 3/5 1/5 2/5
2026-05-20 B+ 3/5 4/5 4/5 5/5 3/5 1/5 2/5
2026-05-19 B+ 3/5 4/5 4/5 5/5 3/5 1/5 2/5
2026-05-18 B+ 3/5 4/5 4/5 5/5 3/5 1/5 2/5
2026-05-15 A- 4/5 4/5 4/5 5/5 3/5 2/5 2/5
2026-05-13 A- 4/5 4/5 4/5 5/5 3/5 2/5 2/5
2026-05-12 A- 4/5 4/5 4/5 5/5 3/5 2/5 2/5
2026-05-11 A- 4/5 4/5 4/5 5/5 3/5 2/5 2/5
2026-05-08 A- 4/5 4/5 4/5 5/5 3/5 2/5 2/5
2026-05-07 A- 4/5 4/5 4/5 5/5 3/5 2/5 2/5
2026-05-06 A- 4/5 4/5 4/5 5/5 3/5 2/5 2/5
2026-05-05 A- 4/5 4/5 4/5 5/5 3/5 2/5 2/5
2026-05-04 A- 4/5 4/5 4/5 5/5 3/5 2/5 2/5
2026-04-30 A- 4/5 4/5 4/5 5/5 3/5 2/5 2/5
2026-04-29 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-04-28 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-04-27 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-04-24 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-04-23 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-04-22 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-04-21 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-04-20 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-04-17 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5
2026-04-16 B+ 3/5 4/5 4/5 5/5 2/5 2/5 2/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
19.77M
OE per share TTM
0.75
Owner's Yield
5.19%
Maintenance CapEx ratio
37.40%
Maint CapEx / Avg PPE
5.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 58 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares MSCI Finland ETF EFNL 0.38% 933.6K 0.53%
2 Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF Dist MMS.PA 0.05% 361.5K 0.40%
3 iShares MSCI EMU Small Cap UCITS ETF CES1.L 0.05% 531.4K 0.58%
4 UBS MSCI EMU Small Cap UCITS ETF EUR dis UEFD.DE 0.05% 347.4K 0.33%
5 Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L 0.02% 668.1K 0.30%
6 iShares MSCI Europe Small-Cap ETF IEUS 0.02% 30.0K 0.41%
7 Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA 0.02% 52.2K 0.23%
8 Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE 0.02% 52.2K 0.23%
9 State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE 0.01% 96.2K 0.30%
10 Schwab International Small-Cap Equity ETF SCHC 0.01% 546.6K 0.06%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
103.7K
Shares Outstanding
26.60M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Jouni Toijala President & Chief Executive Officer 438.9K male
Erkki Tala Vice President of Products, Brand & Marketing — male
Hanna Vuornos Vice President of People & Culture — female
Ari Isomäki Vice President of Operations — male
Juha Jaatinen Interim Chief Financial Officer — male
Robin Pulkkinen Chief Financial Officer — male
John Floyd Vice President of Sales — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Specialties